FDA Approves Radiohybrid PET Diagnostic Agent Posluma for PSMA-Positive Lesions in Prostate Cancer
May 30th 2023The PET diagnostic imaging agent, flotufolastat F 18 injection has been approved by the FDA for the identification of prostate-specific membrane antigen–positive lesions in men with prostate cancer
Epcoritamab Obtains Accelerated Approval for Relapsed/Refractory DLBCL
May 19th 2023The FDA has granted epcoritamab accelerated approval for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. The prescribing label comes with boxed warnings for cytokine release syndrome and neurologic problems.
Addition of Cabozantinib to Nivolumab/Ipilimumab Boosts PFS, But also AEs, in Advanced RCC
May 19th 2023Cabozantinib, in combination with nivolumab and ipilimumab, improved progression-free survival in patients with advanced renal cell carcinoma, but the rate of grade 3/4 adverse events was 79%.